Jorge Ergui-Arbizu

Jorge Ergui-Arbizu

Auto-generated profile, based on publicly available information

Jorge Ergui-Arbizu

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2026 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
AGAdrián Gil-Korilis
Adrián Gil-Korilis
JEJorge Ergui-Arbizu
Jorge Ergui-Arbizu
PHPetr Hanak
Petr Hanak
NDNatálie Danešová
Natálie Danešová
KTKristyna Tomasova
Kristyna Tomasova
SVSona Vodenkova
Sona Vodenkova
Background: Telomere shortening and mitochondrial dysfunction are well-known independent contributors to many diseases, but emerging evidence suggests a reciprocal relationship between the two processes. The role of the so-called telomere-mitochondrial axis in colorectal cancer (CRC) remains largely unknown. Methods: This prospective cohort study screened CRC patients who underwent surgery, from whom peripheral blood, intestinal mucosa, and tumor samples were collected. Colonoscopically confirmed cancer- and adenoma-free healthy individuals were screened as controls, from whom peripheral blood and intestinal mucosa samples were obtained. Relative mitochondrial DNA copy number (mtDNA-CN) and relative telomere length (RTL) were measured in all samples by real-time quantitative polymerase chain reaction and were further compared and correlated considering clinical data. Relative mtDNA-CN was quantified using both TaqMan probes and SYBR Green to compare both methods. Finally, multivariable analyses were conducted to investigate the association between both biomarkers and the risk of tumor recurrence and mortality. Results: A total of 166 CRC patients and 61 healthy individuals were included in the study. In TNM stage I patients, relative mtDNA-CN and RTL were negatively correlated with each other in intestinal mucosa (ρ = -0.77, p < 0.0001), tumor tissue (ρ = -0.41, p = 0.032), and the tumor-to-intestinal mucosa ratio (ρ = -0.39, p = 0.046). However, these associations disappeared with increasing TNM stage, suggesting a dysregulation of the telomere-mitochondrial axis in advanced disease. Higher relative mtDNA-CN in blood was associated with a lower risk of disease recurrence even after adjusting for multiple covariates (HR = 0.43, 95% CI 0.20–0.97, p = 0.041), highlighting its potential use as a prognostic tool. The quantification of mtDNA-CN performed by both methods -TaqMan probes and SYBR Green- was shown to be positively correlated ( p < 0.01). Relative mtDNA-CN and RTL were found to be tissue-dependent in both CRC patients and healthy controls. Conclusions: This study provides a novel contribution to the understanding of the almost unexplored telomere-mitochondrial axis in CRC, highlighting its potential role in disease progression and prognosis. Graphical Created with https://www.BioRender.com .

19 August 2024 in Bioactivities
Verified
Journal Article
Open access
AGAdrián Gil-Korilis
Adrián Gil-Korilis
JEJorge Ergui-Arbizu
Jorge Ergui-Arbizu
Silver nanoparticles (AgNPs) are known for their broad scientific and technological applications, among which those related to their bioactivity stand out the most. Its antimicrobial, antioxidant, anti-inflammatory, anti-obesity, antifouling, and biosorption properties have been widely studied and analyzed. Furthermore, numerous strategies are being investigated to overcome the main limitation of AgNPs, their cytotoxicity, such as the development of green chemistry synthesis methods using plant extracts or the use of support materials for controlled release of nanoparticles. However, the methodologies currently used in this line of research limit these nanomaterials from eventually being used in the clinic. It is necessary to implement animal models and interdisciplinary collaboration with biomedical research groups to develop therapies based on AgNPs that may be able to have an impact on the health of patients.